Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia in the treatment of advanced ovarian cancer

Ovarian cancer is a clinical type of gynecological malignant tumor with poor prognosis and a high mortality rate. At present, the primary treatment method used is surgery, with chemotherapy as an ajdunctive therapy. Thus, new short-term treatments should be identified. The aim of the present study w...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2016-05, Vol.11 (5), p.3287-3292
Main Authors: ZHANG, TING, PAN, QIONG, XIAO, SONGSHU, LI, LIJIE, XUE, MIN
Format: Article
Language:English
Subjects:
Abdomen
advanced ovarian cancer
Cancer therapies
Chemotherapy
Cisplatin
combination therapy
Docetaxel
Dosage and administration
Drug therapy
Gynecological cancer
Health aspects
hyperthermia
intraperitoneal hyperthermic perfusion
Medical prognosis
Methods
Oncology
Ovarian cancer
Patient outcomes
Patients
Physiology
Prognosis
Short term
Tumors
Validity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ovarian cancer is a clinical type of gynecological malignant tumor with poor prognosis and a high mortality rate. At present, the primary treatment method used is surgery, with chemotherapy as an ajdunctive therapy. Thus, new short-term treatments should be identified. The aim of the present study was to investigate the short-term curative effects and safety of docetaxel combined with intraperitoneal cisplatin chemotherapy and hyperthermia treatment of advanced ovarian cancer. A total of 112 cases of advanced (stage III-IV) ovarian cancer patients confirmed by clinical diagnosis between October 2014 and December 2015 were included in the study. The patients were randomly divided into the study and control groups (n=56 cases). The control group was treated with docetaxel and intraperitoneal cisplatin hyperthermic perfusion chemotherapy, while the study group was treated with docetaxel venous chemotherapy and intraperitoneal cisplatin cyclical hyperthermic perfusion chemotherapy with BR-TRG-1 body cavity hyperthermic perfusion treatment system. Clinical treatment results for short-term curative effects and adverse reactions were compared and analyzed 8 weeks after treatment. The total effective rate of the study and control groups were 87.5 and 62.5%, respectively, and the difference was statistically significant (P
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2016.4414